Organigram (TSE:OGI – Free Report) had its price target raised by Canaccord Genuity Group from C$3.25 to C$3.60 in a report issued on Wednesday, BayStreet.CA reports. They currently have a speculative buy rating on the stock.
Separately, Jefferies Financial Group cut their price objective on shares of Organigram from C$4.40 to C$4.35 in a report on Friday, May 17th.
Organigram Price Performance
Insider Transactions at Organigram
In related news, Senior Officer Paolo De Luca sold 11,899 shares of Organigram stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of C$2.61, for a total value of C$31,056.39. Corporate insiders own 27.16% of the company’s stock.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
See Also
- Five stocks we like better than Organigram
- Buy P&G Now, Before It Sets A New All-Time High
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 8/12 – 8/16
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.